📊 SLNO Key Takeaways
Is Soleno Therapeutics Inc. (SLNO) a Good Investment?
Soleno demonstrates strong balance sheet health, exceptional liquidity (5.8x current ratio), and solid free cash flow generation ($46.7M). However, the negative gross margin (-0.0%) and unexplained 13,024% revenue spike raise material concerns about operational sustainability and profitability quality, despite positive net income.
Why Buy Soleno Therapeutics Inc. Stock? SLNO Key Strengths
- Exceptional liquidity with 5.80x current ratio and $70.1M cash on hand
- Strong free cash flow of $46.7M with 24.5% FCF margin demonstrates cash generation capability
- Conservative capital structure with 0.11x debt-to-equity ratio and low financial risk
- Positive net income of $20.9M and operating cash flow of $46.8M indicate functioning core operations
- Minimal capital expenditure requirements ($73.0K) suggest efficient asset base
SLNO Stock Risks: Soleno Therapeutics Inc. Investment Risks
- Negative gross margin (-0.0%) indicates products are unprofitable at unit level, unsustainable without explanation
- Anomalous 13,024% YoY revenue growth suggests acquisition/one-time event; quality and sustainability of growth unclear
- Weak interest coverage ratio of 1.7x leaves limited margin of safety for debt service
- Disconnect between negative gross profit and positive net income suggests non-operating gains masking operational weakness
- Pharmaceutical sector regulatory and approval risks; high insider activity (11 Form 4s in 90 days) warrants monitoring
Key Metrics to Watch
- Gross margin trend - must turn positive for sustainable profitability
- Revenue composition and sustainability - breakdown of the 13,024% YoY increase (acquisition vs. organic growth)
- Interest coverage ratio improvement - need expansion above 1.7x for debt safety
- Operating cash flow consistency - verify $46.8M is recurring not anomalous
- COGS and manufacturing efficiency trends - critical to understand negative gross margin drivers
Soleno Therapeutics Inc. (SLNO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 24.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.80x current ratio provides a solid financial cushion.
SLNO Profit Margin, ROE & Profitability Analysis
SLNO vs Healthcare Sector: How Soleno Therapeutics Inc. Compares
How Soleno Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Soleno Therapeutics Inc. Stock Overvalued? SLNO Valuation Analysis 2026
Based on fundamental analysis, Soleno Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Soleno Therapeutics Inc. Balance Sheet: SLNO Debt, Cash & Liquidity
SLNO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Soleno Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.36 indicates the company is currently unprofitable.
SLNO Revenue Growth, EPS Growth & YoY Performance
SLNO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $66.0M | -$4.7M | $-0.45 |
| Q2 2025 | $32.7M | -$4.7M | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Soleno Therapeutics Inc. Dividends, Buybacks & Capital Allocation
SLNO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Soleno Therapeutics Inc. (CIK: 0001484565)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SLNO
What is the AI rating for SLNO?
Soleno Therapeutics Inc. (SLNO) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SLNO's key strengths?
Claude: Exceptional liquidity with 5.80x current ratio and $70.1M cash on hand. Strong free cash flow of $46.7M with 24.5% FCF margin demonstrates cash generation capability.
What are the risks of investing in SLNO?
Claude: Negative gross margin (-0.0%) indicates products are unprofitable at unit level, unsustainable without explanation. Anomalous 13,024% YoY revenue growth suggests acquisition/one-time event; quality and sustainability of growth unclear.
What is SLNO's revenue and growth?
Soleno Therapeutics Inc. reported revenue of $190.4M.
Does SLNO pay dividends?
Soleno Therapeutics Inc. does not currently pay dividends.
Where can I find SLNO SEC filings?
Official SEC filings for Soleno Therapeutics Inc. (CIK: 0001484565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SLNO's EPS?
Soleno Therapeutics Inc. has a diluted EPS of $0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SLNO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Soleno Therapeutics Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SLNO stock overvalued or undervalued?
Valuation metrics for SLNO: ROE of 4.6% (sector avg: 15%), net margin of 11.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SLNO stock in 2026?
Our dual AI analysis gives Soleno Therapeutics Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SLNO's free cash flow?
Soleno Therapeutics Inc.'s operating cash flow is $46.8M, with capital expenditures of $73.0K. FCF margin is 24.5%.
How does SLNO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 11.0% (avg: 12%), ROE 4.6% (avg: 15%), current ratio 5.80 (avg: 2).